SMARCA2/4 dual degrader(Aurigene Oncology)

N/A

Report date: 2025/11/24 11:13:05
NME

Base Information

Drug NameSMARCA2/4 dual degrader(Aurigene Oncology)
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionProbable global transcription activator SNF2L2 degradersTranscription activator BRG1 degraders
TargetsProbable global transcription activator SNF2L2Transcription activator BRG1
Therapy Area/IndicationsProstatic NeoplasmsMultiple MyelomaLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAurigene Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAurigene Oncology Ltd
Inactive CompaniesN/A
Active IndicationsProstatic NeoplasmsMultiple MyelomaLymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A